{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:59:57Z","timestamp":1773403197451,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:00:00Z","timestamp":1557187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Deletion of long arm of chromosome 20 [del(20q)] is the second most frequent recurrent chromosomal abnormality in hematological malignancies. It is detected in 10% of myeloproliferative neoplasms, 4\u20135% of myelodysplastic syndromes, and 1\u20132% of acute myeloid leukaemia. Recurrent, non-random occurrence of del(20q) indicates that it is a pathogenic driver in myeloid malignancies. Genetic mapping of patient samples has identified two regions of interest on 20q \u2013 the \u201cCommon Deleted Region\u201d (CDR) and \u201cCommon Retained Region\u201d (CRR), which was often amplified. We proposed that the CDR contained tumor suppressor gene(s) (TSG) and the CRR harbored oncogene(s); loss of a TSG together with over-expression of an oncogene favored development of myeloid malignancies. Protein Tyrosine Phosphatase Receptor T (PTPRT) and Hemopoietic cell kinase (HCK) were identified to be the likely candidate TSG and oncogene respectively. Retroviral transduction of HCK into PTPRT-null murine LKS+ stem and progenitor cells resulted in hyperproliferation in colony forming assays and hyperphosphorylation of intracellular STAT3. Furthermore, over half of the murine recipients of these transduced cells developed erythroid hyperplasia, polycythemia and splenomegaly at 12 months, although no leukemic phenotype was observed. The findings suggested that HCK amplification coupled with PTPRT loss in del(20q) leads to development of a myeloproliferative phenotype.<\/jats:p>","DOI":"10.1038\/s41598-019-43373-6","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T08:32:13Z","timestamp":1557304333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hemopoietic Cell Kinase amplification with Protein Tyrosine Phosphatase Receptor T depletion leads to polycythemia, aberrant marrow erythoid maturation, and splenomegaly"],"prefix":"10.1038","volume":"9","author":[{"given":"Matthew","family":"Ku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0294-5051","authenticated-orcid":false,"given":"Ruth N.","family":"MacKinnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meaghan","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9031","authenticated-orcid":false,"given":"Carl","family":"Walkley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4965-7148","authenticated-orcid":false,"given":"Heung-Chin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda J.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6593-3168","authenticated-orcid":false,"given":"Louise E.","family":"Purton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshal","family":"Nandurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,7]]},"reference":[{"issue":"1","key":"43373_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/0165-4608(93)90075-W","volume":"68","author":"GW Dewald","year":"1993","unstructured":"Dewald, G. W., Schad, C. R., Lilla, V. C. & Jalal, S. M. Frequency and photographs of HGM11 chromosome anomalies in bone marrow samples from 3,996 patients with malignant hematologic neoplasms. . Cancer Genet Cytogenet. 68(1), 60\u201369 (1993).","journal-title":". Cancer Genet Cytogenet."},{"issue":"34","key":"43373_CR2","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1038\/sj.onc.1203728","volume":"19","author":"AJ Bench","year":"2000","unstructured":"Bench, A. J. et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC\/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 19(34), 3902\u20133913 (2000).","journal-title":"Oncogene"},{"issue":"2","key":"43373_CR3","first-page":"127","volume":"33","author":"P Fenaux","year":"1996","unstructured":"Fenaux, P., Morel, P. & Lai, J. L. Cytogenetics of myelodysplastic syndromes. Semin Hematol. 33(2), 127\u2013138 (1996).","journal-title":"Semin Hematol."},{"issue":"6 suppl","key":"43373_CR4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/1097-0142(19920915)70:4+<1701::AID-CNCR2820701609>3.0.CO;2-S","volume":"70","author":"S Heim","year":"1992","unstructured":"Heim, S. & Mitelman, F. Cytogenetic analysis in the diagnosis of acute leukemia. Cancer 70(6 suppl), 1701\u20131709 (1992).","journal-title":"Cancer"},{"key":"43373_CR5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/gcc.20806","volume":"49","author":"RN MacKinnon","year":"2010","unstructured":"MacKinnon, R. N. et al. The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion. Genes, Chromosomes and Cancer 49, 998\u20131013, https:\/\/doi.org\/10.1002\/gcc.20806 (2010).","journal-title":"Genes, Chromosomes and Cancer"},{"key":"43373_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/ajcp\/106.5.680","volume":"106","author":"PJ Kurtin","year":"1996","unstructured":"Kurtin, P. J., Dewald, G., Shields, D. J. & Hanson, C. A. Hematologic disorders associated with deletions of chromosome 20q: A clinicopathologic study of 107 patients. Am J Clin Pathol 106, 680\u2013688 (1996).","journal-title":"Am J Clin Pathol"},{"key":"43373_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1365-2141.1996.d01-1896.x","volume":"95","author":"FA Asimakopoulos","year":"1996","unstructured":"Asimakopoulos, F. A. & Green, A. Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol 95, 219\u2013226 (1996).","journal-title":"Br J Haematol"},{"key":"43373_CR8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1172\/JCI66113","volume":"123","author":"A Aziz","year":"2013","unstructured":"Aziz, A. et al. Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. The Journal of Clinical Investigation 123, 2169\u20132182, https:\/\/doi.org\/10.1172\/JCI66113 (2013).","journal-title":"The Journal of Clinical Investigation"},{"issue":"4","key":"43373_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc1837","volume":"6","author":"A \u00d6stman","year":"2006","unstructured":"\u00d6stman, A., Hellberg, C. & B\u00f6hmer, F. D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6(4), 307\u2013320 (2006).","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"43373_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/0955-0674(95)80106-5","volume":"7","author":"SM Brady-Kalnay","year":"1995","unstructured":"Brady-Kalnay, S. M. & Tonks, N. K. Protein tyrosine phosphatases as adhesion receptors. Curr. Opin. Cell Biol 7(5), 650\u2013657 (1995).","journal-title":"Curr. Opin. Cell Biol"},{"key":"43373_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/sj.emboj.7600974","volume":"25","author":"AR Aricescu","year":"2006","unstructured":"Aricescu, A. R. et al. Molecular analysis of receptor protein tyrosine phosphatase mu-mediated cell adhesion. EMBO J. 25, 701\u2013712 (2006).","journal-title":"EMBO J."},{"key":"43373_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/15419061003653771","volume":"16","author":"P Zhang","year":"2009","unstructured":"Zhang, P. et al. Cancer-derived mutations in the fibronectin III repeats of PTPRT\/PTPrho inhibit cell-cell aggregation. Cell communication & adhesion 16, 146\u2013153, https:\/\/doi.org\/10.3109\/15419061003653771 (2009).","journal-title":"Cell communication & adhesion"},{"key":"43373_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.brainres.2006.07.122","volume":"1116","author":"JA Besco","year":"2006","unstructured":"Besco, J. A., Hooft van Huijsduijnen, R., Frostholm, A. & Rotter, A. Intracellular substrates of brain-enriched receptor protein tyrosine phosphatase rho (RPTPrho\/PTPRT). Brain research 1116, 50\u201357, https:\/\/doi.org\/10.1016\/j.brainres.2006.07.122 (2006).","journal-title":"Brain research"},{"key":"43373_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2174\/187152011794941244","volume":"11","author":"SE Craig","year":"2011","unstructured":"Craig, S. E. & Brady-Kalnay, S. M. Tumor-derived extracellular fragments of receptor protein tyrosine phosphatases (RPTPs) as cancer molecular diagnostic tools. Anti-cancer agents in medicinal chemistry 11, 133\u2013140 (2011).","journal-title":"Anti-cancer agents in medicinal chemistry"},{"key":"43373_CR15","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.cellsig.2010.06.001","volume":"22","author":"MJ Chagnon","year":"2010","unstructured":"Chagnon, M. J. et al. Receptor tyrosine phosphatase sigma (RPTPsigma) regulates, p250GAP, a novel substrate that attenuates Rac signaling. Cellular signalling 22, 1626\u20131633, https:\/\/doi.org\/10.1016\/j.cellsig.2010.06.001 (2010).","journal-title":"Cellular signalling"},{"key":"43373_CR16","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1038\/emboj.2009.289","volume":"28","author":"SH Lim","year":"2009","unstructured":"Lim, S. H. et al. Synapse formation regulated by protein tyrosine phosphatase receptor T through interaction with cell adhesion molecules and Fyn. EMBO J 28, 3564\u20133578, https:\/\/doi.org\/10.1038\/emboj.2009.289 (2009).","journal-title":"EMBO J"},{"key":"43373_CR17","unstructured":"Brady-Kalnay, S. M. Protein tyrosine phosphatases. In Cell Adhesion: Frontiers in Molecular Biology (Beckerle, M., ed.). Oxford University Press, Oxford pp. 217\u2013258 (2001)."},{"key":"43373_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/sj.cgt.7700828","volume":"12","author":"ST Jacob","year":"2005","unstructured":"Jacob, S. T. & Motiwala, T. Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer gene therapy 12, 665\u2013672, https:\/\/doi.org\/10.1038\/sj.cgt.7700828 (2005).","journal-title":"Cancer gene therapy"},{"key":"43373_CR19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1126\/science.1096096","volume":"304","author":"Z Wang","year":"2004","unstructured":"Wang, Z. et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (New York, N.Y.) 304, 1164\u20131166, https:\/\/doi.org\/10.1126\/science.1096096 (2004).","journal-title":"Science (New York, N.Y.)"},{"key":"43373_CR20","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1073\/pnas.0914884107","volume":"107","author":"Y Zhao","year":"2010","unstructured":"Zhao, Y. et al. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proceedings of the National Academy of Sciences of the United States of America 107, 2592\u20132597, https:\/\/doi.org\/10.1073\/pnas.0914884107 (2010).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"43373_CR21","unstructured":"Forbes, S. A. et al. The catalogue of somatic mutations in cancer (COSMIC). In: Current Protocols in Humum Genetics. New York: John Wiley & Sons, Chapter 10, Units 10, 11 (2008)."},{"key":"43373_CR22","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1073\/pnas.1319551111","volume":"111","author":"VW Lui","year":"2014","unstructured":"Lui, V. W. et al. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proceedings of the National Academy of Sciences of the United States of America 111, 1114\u20131119, https:\/\/doi.org\/10.1073\/pnas.1319551111 (2014).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"43373_CR23","unstructured":"Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66\u201372, http:\/\/www.nature.com\/nature\/journal\/v456\/n7218\/suppinfo\/nature07485_S1.html (2008)."},{"key":"43373_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000112063","volume":"119","author":"RN MacKinnon","year":"2007","unstructured":"MacKinnon, R. N. & Campbell, L. Dicentric chromosomes and 20q11.2 amplification in MDS\/AML with apparent monosomy 20. Cytogenet Genome Res 119, 211\u2013220 (2007).","journal-title":"Cytogenet Genome Res"},{"key":"43373_CR25","first-page":"2014","volume":"5","author":"M Ku","year":"2014","unstructured":"Ku, M., Wall, M. & Mackinnon, R. Src family kinases and their role in hematological malignancies. Leukemia and Lymphoma online on June 5, 2014 (2014).","journal-title":"Leukemia and Lymphoma online on June"},{"key":"43373_CR26","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.leukres.2012.03.020","volume":"36","author":"JE Vazquez-Franco","year":"2012","unstructured":"Vazquez-Franco, J. E., Reyes-Maldonado, E., Vela-Ojeda, J., Dominguez-Lopez, M. L. & Lezama, R. A. Src, Akt, NF-kappaB, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia. Leuk Res 36, 862\u2013867, https:\/\/doi.org\/10.1016\/j.leukres.2012.03.020 (2012).","journal-title":"Leuk Res"},{"issue":"15","key":"43373_CR27","first-page":"3589","volume":"56","author":"S Danhauser-Riedl","year":"1996","unstructured":"Danhauser-Riedl, S., Warmuth, M., Druker, B. J., Emmerich, B. & Hallek, M. Activation of Src kinases p53\/56 lyn and p59hck by p210bcr\/abl in myeloid cells. Cancer research 56(15), 3589\u201396 (1996).","journal-title":"Cancer research"},{"key":"43373_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.leukres.2010.06.030","volume":"35","author":"S Hayette","year":"2011","unstructured":"Hayette, S. et al. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. Leuk Res 35, 38\u201343, https:\/\/doi.org\/10.1016\/j.leukres.2010.06.030 (2011).","journal-title":"Leuk Res"},{"key":"43373_CR29","doi-asserted-by":"publisher","first-page":"21446","DOI":"10.1074\/jbc.M109.090043","volume":"285","author":"T Pene-Dumitrescu","year":"2010","unstructured":"Pene-Dumitrescu, T. & Smithgall, T. E. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 285, 21446\u201321457, https:\/\/doi.org\/10.1074\/jbc.M109.090043 (2010).","journal-title":"J Biol Chem"},{"key":"43373_CR30","doi-asserted-by":"publisher","first-page":"7055","DOI":"10.1038\/onc.2008.330","volume":"27","author":"T Pene-Dumitrescu","year":"2008","unstructured":"Pene-Dumitrescu, T., Peterson, L. F., Donato, N. J. & Smithgall, T. E. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene 27, 7055\u20137069, https:\/\/doi.org\/10.1038\/onc.2008.330 (2008).","journal-title":"Oncogene"},{"issue":"5","key":"43373_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ng1343","volume":"36","author":"Y Hu","year":"2004","unstructured":"Hu, Y. et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL 1 induced B lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36(5), 453\u201361 (2004).","journal-title":"Nat Genet"},{"key":"43373_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/btt.s30182","volume":"7","author":"GK Amsberg","year":"2013","unstructured":"Amsberg, G. K. & Schafhausen, P. Bosutinib in the management of chronic myelogenous leukemia. Biologics: targets & therapy 7, 115\u2013122, https:\/\/doi.org\/10.2147\/btt.s30182 (2013).","journal-title":"Biologics: targets & therapy"},{"key":"43373_CR33","doi-asserted-by":"publisher","first-page":"17ra19","DOI":"10.1126\/scitranslmed.3000349","volume":"2","author":"Y Saito","year":"2010","unstructured":"Saito, Y. et al. Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells. Science translational medicine 2, 17ra19, https:\/\/doi.org\/10.1126\/scitranslmed.3000349 (2010).","journal-title":"Science translational medicine"},{"key":"43373_CR34","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1073\/pnas.0611665104","volume":"104","author":"X Zhang","year":"2007","unstructured":"Zhang, X. et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proceedings of the National Academy of Sciences of the United States of America 104, 4060\u20134064, https:\/\/doi.org\/10.1073\/pnas.0611665104 (2007).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"43373_CR35","doi-asserted-by":"publisher","first-page":"45680","DOI":"10.1074\/jbc.M204255200","volume":"277","author":"SJ Schreiner","year":"2002","unstructured":"Schreiner, S. J., Schiavone, A. P. & Smithgall, T. E. Activation of STAT3 by the Src Family Kinase Hck Requires a Functional SH3 Domain. Journal of Biological Chemistry 277, 45680\u201345687, https:\/\/doi.org\/10.1074\/jbc.M204255200 (2002).","journal-title":"Journal of Biological Chemistry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43373-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43373-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43373-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:17:32Z","timestamp":1671268652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43373-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["43373"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-43373-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,7]]},"assertion":[{"value":"6 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7050"}}